BACKGROUND: Aspiration of gastroesophageal refluxate may contribute to lung transplant bronchiolitis obliterans syndrome (BOS). We investigated bile acids in bronchoalveolar lavage fluid (BALF) and studied its role in BOS. MATERIALS AND METHODS: Surveillance pulmonary function tests and BALF were evaluated in 120 lung recipients. BOS-(0p-3) was diagnosed after 6 months' survival. BOS was defined as "early" if diagnosed within 12 months after a transplant. BALF was assayed for differential cell count, bile acids, and interleukins 8 and 15. Bile acids were considered elevated if greater than normal serum levels ( or =8 micromol/L). RESULTS: Elevated BALF bile acids were measured in 20 (17%) of 120 patients. BOS was diagnosed in 36 (34%) of 107 patients and judged "early" in 21 (57%) of 36. Median BALF bile acid values were 1.6 micromol/L (range, 0-32 micromol/L) in BOS patients and 0.3 micromol/L (range, 0-16 micromol/L) in non-BOS patients ( P = .002); 2.6 micromol/L (range, 0-32 micromol/L) in early BOS patients and 0.8 micromol/L (range, 0-4.6 micromol/L) in late BOS patients, ( P = .02). Bile acids correlated with BALF IL-8 and alveolar neutrophilia (r = 0.3, P = .0004, and r = 0.3, P = .004, respectively), but not with IL-15. Freedom from BOS was significantly shortened in patients with elevated BALF bile acids (Cox-Mantel test, P = .0001). CONCLUSIONS: Aspiration of duodenogastroesophageal refluxate is prevalent after lung transplantation and is associated with the development of BOS. Elevated BALF bile acids may promote early BOS development via an inflammatory process, possibly mediated by IL-8 and alveolar neutrophilia.
BACKGROUND: Aspiration of gastroesophageal refluxate may contribute to lung transplant bronchiolitis obliterans syndrome (BOS). We investigated bile acids in bronchoalveolar lavage fluid (BALF) and studied its role in BOS. MATERIALS AND METHODS: Surveillance pulmonary function tests and BALF were evaluated in 120 lung recipients. BOS-(0p-3) was diagnosed after 6 months' survival. BOS was defined as "early" if diagnosed within 12 months after a transplant. BALF was assayed for differential cell count, bile acids, and interleukins 8 and 15. Bile acids were considered elevated if greater than normal serum levels ( or =8 micromol/L). RESULTS: Elevated BALF bile acids were measured in 20 (17%) of 120 patients. BOS was diagnosed in 36 (34%) of 107 patients and judged "early" in 21 (57%) of 36. Median BALF bile acid values were 1.6 micromol/L (range, 0-32 micromol/L) in BOSpatients and 0.3 micromol/L (range, 0-16 micromol/L) in non-BOSpatients ( P = .002); 2.6 micromol/L (range, 0-32 micromol/L) in early BOSpatients and 0.8 micromol/L (range, 0-4.6 micromol/L) in late BOSpatients, ( P = .02). Bile acids correlated with BALF IL-8 and alveolar neutrophilia (r = 0.3, P = .0004, and r = 0.3, P = .004, respectively), but not with IL-15. Freedom from BOS was significantly shortened in patients with elevated BALF bile acids (Cox-Mantel test, P = .0001). CONCLUSIONS: Aspiration of duodenogastroesophageal refluxate is prevalent after lung transplantation and is associated with the development of BOS. Elevated BALF bile acids may promote early BOS development via an inflammatory process, possibly mediated by IL-8 and alveolar neutrophilia.
Authors: A DerHovanessian; S S Weigt; V Palchevskiy; M Y Shino; D M Sayah; A L Gregson; P W Noble; S M Palmer; M C Fishbein; B M Kubak; A Ardehali; D J Ross; R Saggar; J P Lynch; R M Elashoff; J A Belperio Journal: Am J Transplant Date: 2015-10-13 Impact factor: 8.086
Authors: P Marco Fisichella; Christopher S Davis; Peter W Lundberg; Erin Lowery; Ellen L Burnham; Charles G Alex; Luis Ramirez; Karen Pelletiere; Robert B Love; Paul C Kuo; Elizabeth J Kovacs Journal: Surgery Date: 2011-10 Impact factor: 3.982
Authors: C S Davis; J Gagermeier; D Dilling; C Alex; E Lowery; E J Kovacs; R B Love; P M Fisichella Journal: Clin Transplant Date: 2010-03-19 Impact factor: 2.863
Authors: Chad A Newton; Julia Kozlitina; Jefferson R Lines; Vaidehi Kaza; Fernando Torres; Christine Kim Garcia Journal: J Heart Lung Transplant Date: 2017-02-04 Impact factor: 10.247
Authors: P Marco Fisichella; Christopher S Davis; Erin Lowery; Matthew Pittman; James Gagermeier; Robert B Love; Elizabeth J Kovacs Journal: J Surg Res Date: 2012-04-18 Impact factor: 2.192
Authors: Mikio Okazaki; Andrew E Gelman; Jeremy R Tietjens; Aida Ibricevic; Christopher G Kornfeld; Howard J Huang; Steven B Richardson; Jiaming Lai; Joel R Garbow; G Alexander Patterson; Alexander S Krupnick; Steven L Brody; Daniel Kreisel Journal: Am J Respir Cell Mol Biol Date: 2007-08-23 Impact factor: 6.914
Authors: Frederick R Adler; Paul Aurora; David H Barker; Mark L Barr; Laura S Blackwell; Otto H Bosma; Samuel Brown; D R Cox; Judy L Jensen; Geoffrey Kurland; George D Nossent; Alexandra L Quittner; Walter M Robinson; Sandy L Romero; Helen Spencer; Stuart C Sweet; Wim van der Bij; J Vermeulen; Erik A M Verschuuren; Elianne J L E Vrijlandt; William Walsh; Marlyn S Woo; Theodore G Liou Journal: Proc Am Thorac Soc Date: 2009-12
Authors: Daniele De Luca; Angelo Minucci; Enrico Zecca; Marco Piastra; Domenico Pietrini; Virgilio P Carnielli; Cecilia Zuppi; Ascanio Tridente; Giorgio Conti; Ettore D Capoluongo Journal: Intensive Care Med Date: 2008-10-14 Impact factor: 17.440